Publications

        Search PubMed for all articles

  1. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. Nat Rev Clin Oncol. 2021 Sep 10. doi: 10.1038/s41571-021-00549-2. Online ahead of print. PMID: 34508258
  2. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia. Mahauad-Fernandez WD, Rakhra K, Felsher DW. Methods Mol Biol. 2021;2318:297-312. doi: 10.1007/978-1-0716-1476-1_16. PMID: 34019298
  3. Twist1 is required for the development of UVB-induced squamous cell carcinoma. Eguiarte-Solomon F, Blazanin N, Rho O, Carbajal S, Felsher DW, Tran PT, DiGiovanni J. Mol Carcinog. 2021 May;60(5):342-353. doi: 10.1002/mc.23296. Epub 2021 Mar 13. PMID: 33713497
  4. Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging. Chen H, Shou K, Chen S, Qu C, Wang Z, Jiang L, Zhu M, Ding B, Qian K, Ji A, Lou H, Tong L, Hsu A, Wang Y, Felsher DW, Hu Z, Tian J, Cheng Z. Adv Mater. 2021 Apr;33(16):e2006902. doi: 10.1002/adma.202006902. Epub 2021 Mar 12. PMID: 33709533
  5. A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. Hori SS, Tong L, Swaminathan S, Liebersbach M, Wang J, Gambhir SS, Felsher DW. Sci Rep. 2021 Jan 14;11(1):1341. doi: 10.1038/s41598-020-78947-2. PMID: 33446671
  6. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Hepatology. 2021 Jun;73(6):2342-2360. doi: 10.1002/hep.31614. Epub 2021 May 8. PMID: 33140851
  7. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Cui L, Gouw AM, LaGory EL, Guo S, Attarwala N, Tang Y, Qi J, Chen YS, Gao Z, Casey KM, Bazhin AA, Chen M, Hu L, Xie J, Fang M, Zhang C, Zhu Q, Wang Z, Giaccia AJ, Gambhir SS, Zhu W, Felsher DW, Pegram MD, Goun EA, Le A, Rao J. Nat Biotechnol. 2021 Mar;39(3):357-367. doi: 10.1038/s41587-020-0707-9. Epub 2020 Oct 19. PMID: 33077961
  8. MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC. Dhanasekaran R, Park J, Yevtodiyenko A, Bellovin DI, Adam SJ, Kd AR, Gabay M, Fernando H, Arzeno J, Arjunan V, Gryanzov S, Felsher DW. Mol Ther Nucleic Acids. 2020 Sep 4;21:850-859. doi: 10.1016/j.omtn.2020.07.008. Epub 2020 Jul 10. PMID: 32805488
  9. The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship? Mahauad-Fernandez WD, Felsher DW. Cancer Res. 2020 Sep 15;80(18):3799-3802. doi: 10.1158/0008-5472.CAN-20-0787. Epub 2020 Jul 30. PMID: 32732221
  10. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Swaminathan S, Hansen AS, Heftdal LD, Dhanasekaran R, Deutzmann A, Fernandez WDM, Liefwalker DF, Horton C, Mosley A, Liebersbach M, Maecker HT, Felsher DW. Nat Commun. 2020 Jun 5;11(1):2860. doi: 10.1038/s41467-020-16447-7. PMID: 32503978
  11. The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them. Smith MT, Guyton KZ, Kleinstreuer N, Borrel A, Cardenas A, Chiu WA, Felsher DW, Gibbons CF, Goodson WH 3rd, Houck KA, Kane AB, La Merrill MA, Lebrec H, Lowe L, McHale CM, Minocherhomji S, Rieswijk L, Sandy MS, Sone H, Wang A, Zhang L, Zeise L, Fielden M. Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1887-1903. doi: 10.1158/1055-9965.EPI-19-1346. Epub 2020 Mar 9. PMID: 32152214
  12. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Rajan Kd A, Lai I, Gabay M, Tong L, Krishnan M, Park J, Hu T, Barbhuiya MA, Gentles AJ, Kannan K, Tran PT, Felsher DW. Elife. 2020 Jan 14;9:e50731. doi: 10.7554/eLife.50731. PMID: 31933479
  13. Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Li Y, Thomas D, Deutzmann A, Majeti R, Felsher DW, Dill DL. Sci Rep. 2019 Nov 14;9(1):16775. doi: 10.1038/s41598-019-53290-3. PMID: 31727951
  14. Gouw AM, Margulis K, Liu NS, Raman SJ, Mancuso A, Toal GG, Tong L, Mosley A, Hsieh AL, Sullivan DK, Stine ZE, Altman BJ, Schulze A, Dang CV, Zare RN, Felsher DW. Cell Metab. 2019 Sep 3;30(3):556-572.e5. doi: 10.1016/j.cmet.2019.07.012. Epub 2019 Aug 22. PMID: 31447321
  15. Lipid nanoparticles that deliver IL-12 messenge RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma (accepted Journal for ImmunoTherapy of Cancer)
  16. Dhanasekaran R, Gabay-Ryan M, Baylot V, Lai I, Mosley A, Huang X, Zabludoff S, Li J, Kaimal V, Karmali P, Felsher DW. Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget. 2017: 9:5517-5528. PMID: 29464015
  17. Hebb JPO, Mosley AR, Vences-Catalán F, Rajasekaran N, Rosén A, Ellmark P, Felsher DW. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunol Immunother. 2017 Sep 13. doi: 10.1007/s00262-017-2059-y. [Epub ahead of print] PMID: 28905118
  18. Gouw AM, Eberlin LS, Margulis K, Sullivan DK, Toal GG, Tong L, Zare RN, Felsher DW.
    Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4300-4305. doi: 10.1073/pnas.1617709114. Epub 2017 Apr 11. PMID: 28400509
  19. Casey SC, Baylot V, Felsher DW. Trends Immunol. 2017 Apr;38(4):298-305. doi: 10.1016/j.it.2017.01.002. PMID: 28233639
  20. Li Y, Deutzmann A, Felsher DW. BIM-mediated apoptosis and oncogene addiction.  Aging (Albany NY). 2016 Sep 29;8(9):1834-1835. doi: 10.18632/aging.101072. PubMed PMID: 27688082.
  21. Felsher DW, Lowe L. Affordable Cancer Medications Are Within Reach but We Need a Different Approach. J Clin Oncol. 2016 Jun 20;34(18):2194-5. doi: 10.1200/JCO.2016.67.2436. PubMed PMID: 27161965.
  22. Li Y, Deutzmann A, Choi PS, Fan AC, Felsher DW. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. Oncotarget. 2016 May 10;7(19):26926-34. doi: 10.18632/oncotarget.8731. PubMed PMID: 27095570.
  23. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. PubMed PMID: 26966191; PubMed Central PMCID: PMC4940030.
  24. Gouw AM, Toal GG, Felsher DW. Metabolic vulnerabilities of MYC-induced cancer. Oncotarget. 2016 May 24;7(21):29879-80. doi: 10.18632/oncotarget.7223. PubMed PMID: 26863454.
  25. Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, van Riggelen J, Plevritis S, Felsher DW. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget. 2015 Feb 28;6(6):3563-77. PubMed PMID: 25784651; PubMed Central PMCID: PMC4414137.
  26. Li Y, Choi PS, Felsher DW. Oncogene addiction: resetting the safety switch? Oncotarget. 2014 Sep 30;5(18):7986-7. PubMed PMID: 25275297; PubMed Central PMCID: PMC4226662.
  27. Li Y, Casey SC, Choi PS, Felsher DW. miR-17-92 explains MYC oncogene addiction. Mol Cell Oncol. 2014 Dec 31;1(4):e970092. doi: 10.4161/23723548.2014.970092. PubMed PMID: 27308380; PubMed Central PMCID: PMC4905255.
  28. Li Y, Choi PS, Felsher DW. Oncogene addiction: resetting the safety switch? Oncotarget. 2014 Sep 20. [Epub ahead of print] PubMed PMID: 25275297.
  29. Li Y, Choi PS, Casey SC, Felsher DW. Activation of cre recombinase alone can induce complete tumor regression. PLoS One. 2014 Sep 10;9(9):e107589. doi: 10.1371/journal.pone.0107589. eCollection 2014. PubMed PMID: 25208064; PubMed Central PMCID: PMC4160265.
  30. Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell. 2014 Aug 11;26(2):262-72. doi: 10.1016/j.ccr.2014.06.014. PubMed PMID: 25117713.
  31. Casey SC, Li Y, Fan AC, Felsher DW. Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer. 2014 Jul 15;2:24. doi: 10.1186/2051-1426-2-24. eCollection 2014. Review. PubMed PMID: 25089198; PubMed Central PMCID: PMC4118610.
  32. Choi PS, Li Y, Felsher DW. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3316-24. doi: 10.1073/pnas.1406123111. Epub 2014 Jul 28. PubMed PMID: 25071175; PubMed Central PMCID: PMC4136575.
  33. Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN. Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc  Natl Acad Sci U S A. 2014 Jul 22;111(29):10450-5. doi: 10.1073/pnas.1409778111. Epub 2014 Jul 3. PubMed PMID: 24994904; PubMed Central PMCID: PMC4115527.
  34. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a014241. doi: 10.1101/cshperspect.a014241. PubMed PMID: 24890832.
  35. Ye D, Shuhendler AJ, Cui L, Tong L, Tee SS, Tikhomirov G, Felsher DW, Rao J. Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat Chem. 2014 Jun;6(6):519-26. doi: 10.1038/nchem.1920. Epub 2014 Apr 28. PubMed PMID: 24848238; PubMed Central PMCID: PMC4031611.
  36. Casey SC, Li Y, Felsher DW. An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res. 2014 May;58(2-3):282-91. doi: 10.1007/s12026-014-8503-6. PubMed PMID: 24791942.
  37. Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis. J Intern Med. 2014 Jul;276(1):52-60. doi: 10.1111/joim.12237. Review. PubMed PMID:  24645771; PubMed Central PMCID: PMC4065197.
  38. Cao Z, Ding BS, Guo P, Lee SB, Butler JM, Casey SC, Simons M, Tam W, Felsher  DW, Shido K, Rafii A, Scandura JM, Rafii S. Angiocrine factors deployed by tumor  vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell. 2014 Mar 17;25(3):350-65. doi: 10.1016/j.ccr.2014.02.005. PubMed PMID: 24651014; PubMed Central PMCID: PMC4017921.
  39. Nwabugwu CI, Rakhra K, Felsher DW, Paik DS. A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:4529-32. doi: 10.1109/EMBC.2013.6610554. PubMed PMID: 24110741.
  40. Rakhra K, Felsher DW. Generation of a tetracycline regulated mouse model of MYC-induced T-cell acute lymphoblastic leukemia. Methods Mol Biol. 2013;1012:221-35. doi: 10.1007/978-1-62703-429-6_15. PubMed PMID: 24006068.
  41. Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, Castaneda R, Hazard FK, Tong L, Lenkov OD, Felsher DW, Rao J, Daldrup-Link HE. Development  of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small. 2014 Feb 12;10(3):566-75, 417. doi: 10.1002/smll.201301456. Epub  2013 Aug 27. PubMed PMID: 24038954; PubMed Central PMCID: PMC3946335.
  42. Fan AC, O'Rourke JJ, Praharaj DR, Felsher DW. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs. 2013 Nov;22(11):1495-509. doi: 10.1517/13543784.2013.829453. Epub 2013 Aug 12. Review. PubMed PMID: 23937225; PubMed Central PMCID: PMC4111569.
  43. Casey SC, Bellovin DI, Felsher DW. Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol. 2013 Apr;25(2):246-58. doi: 10.1016/j.coi.2013.02.003. Epub 2013 Apr 6. Review. PubMed PMID: 23571026; PubMed Central PMCID: PMC3683588.

        Search PubMed for all articles